Advanced Search
Wang Huimin, Liao Meilin, Chen Yurong, et al. The Response Rate of High Dose Epirubicin in Comparison with Conventional Dose on NSCLC[J]. Cancer Research on Prevention and Treatment, 1999, 26(2): 133-135.
Citation: Wang Huimin, Liao Meilin, Chen Yurong, et al. The Response Rate of High Dose Epirubicin in Comparison with Conventional Dose on NSCLC[J]. Cancer Research on Prevention and Treatment, 1999, 26(2): 133-135.

The Response Rate of High Dose Epirubicin in Comparison with Conventional Dose on NSCLC

More Information
  • Objective: Our objective is to evaluate the efficacy of high close epirubicin combination chemtherapy in comparison with conventional dose in the treatment of non-small cell lung cancer (NSCLC) and to observe the toxicity between the two groups. Methods:30 patients with NSCLC (stage II一IV) were randomized into two groups.Each group had 15 patients. One group was treated with high dose epirubicin (HD EPI: 100mg/M2).Another group was used with conventional dose epirubicin(CD EPI: 75mg/ MZ).A ll these 30 patient s were treated with MEP (mi tomycin C+ epirubicin+ cisplatin)regimen for 2 cycles. Results: The results showed that the response rates CRR) of high close and conventional dose epirubicin groups were of 40.0% and 20.0%,respectively. The RR of HD EPI was much higher than that of CD EPI, though there was no statistical difference between the two groupe (P> 0.05).The HD EPI group had more oral mucositis. The difference was statistically significant (P<0.05).However, there was no notable statistical difference(P>0. 05)between the two groups regarding other toxicity such as gastrointestinal tract reaction, myelosuppression, phlebitis and alopecia.Obvious cardiotoxicity was not found in all patients. Conclusion; The response rate of the HD EPI group is better than that of the CD EPI group acxeording to the actual value. There is no siginificant statisitical difference betweenn the two groups concerning the main toxicity .Thus, these results are worthwhile for dinicalextensive application and further study.
  • [1]
    Weiss RB.The anthracyclines:Wil we ever find a better do xorubicin ? Semis Onceh 1992, 19(6):670
    [2]
    Rosen HR,Minow RA,Leier CV,et al.Epirubicin and Doxorrubicin:A comparison of the characteristic therapeutic activity and toxicity.Cancer Treat Rev,1993,19(3):197
    [3]
    林震琼,徐昌文,等.小细胞肺癌化疗后的病理学观察--附48例分析.中华肿瘤杂志,1988, 6(10):452-454
    [4]
    Martoni A,Melotti B, et al. High-dose epirubicin for untreated patients with advanced tumours a phase I study.Eur-J-Cancer,1990, 26(11-12):1137-1140
    [5]
    Cersoimo RJ,et al.Epirubicin:a review of the pliarmacology,clinical activity,and adverse effects of anadriamvcin anabgue.,J-Clim-On-col, 1986,4:425-439
    [6]
    Martoni A, et al.Activiy of high dose epimbicin in advanced non-small-cell lung Cancer. Eur-J-Cancer,1991, 27(10):1231-1234
    [7]
    Martoiu A. Guaraldi M, et al.A phrase II study of high- dose epirubici plus cisplatinum in advanced non-small-cell lung cancer (NSCLC),Ann-oncol 1992, 12,3(10):864-866

Catalog

    Article views (1155) PDF downloads (350) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return